Celltheon

  • HOME
  • SERVICES
    • Transient Transfection
    • Cell Line Development
    • Process Development
    • Bioproduction
  • Products and Technology
    • suPRE™ Elements
    • Celltheon SMART™ vectors
    • Celltheon Supercells™
  • NEWS & EVENTS
  • EMPLOYMENT
  • CONTACT
  • HOME
  • SERVICES
    • Transient Transfection
    • Cell Line Development
    • Process Development
    • Bioproduction
  • Products and Technology
    • suPRE™ Elements
    • Celltheon SMART™ vectors
    • Celltheon Supercells™
  • NEWS & EVENTS
  • EMPLOYMENT
  • CONTACT

​​
​​​​CELLTHEON SMART™  ​
TECHNOLOGY IS TAKING BIOTHERAPEUTIC DEVELOPMENT TO THE NEXT LEVEL
​

ABOUT CELLTHEON

Located in the San Francisco Bay Area – a center of excellence in Biotechnology, Celltheon is a leader in mammalian expression technologies. Founded in 2012, the company's vision was to develop a mammalian expression platform that addressed the industry's key pain points:
  • Low Expression
  • Sub-optimal Product Quality
  • Cell Line Instability
  • Difficulty with process transferability & scalability

As such, the Celltheon SMART™ Technology Platform was developed to address each of these key challenges. Celltheon leverages its platform technology to provide custom cell line and process development services for the biotech/ pharmaceutical industry. Several novel and biosimilar molecules have been developed using the platform such as monoclonal antibodies, Fabs, antibody fragments, difficult to express proteins, etc. In addition, Celltheon has experience with several disease indications such as oncology, inflammation, neurodegeneration, obesity, and various lysosomal storage disorders.

Since its inception, Celltheon has worked on >60 client projects ranging from pre-clinical to clinical stage therapeutics. In addition, two molecules have advanced to BLA and are awaiting commercial approval. Celltheon has granted 11 commercial licenses to date in addition to several R&D licenses. 

The Celltheon SMART™ Technology Platform and services significantly reduce time and costs associated with development of biotherapeutics. As an innovative technology development company, Celltheon continues to develop cutting-edge technologies that improve the manufacturability and efficacy of biologics. Celltheon has filed several patent applications and has received broad, granted patents that encompass many applications of its platform technologies. For more information, please contact us at info@celltheon.com.


​TEAM

Picture
Amita Goel
​CEO
Picture
Guriq Basi, PhD
Antibody Engineering

Picture
Murali Dharan, MD
Board Member
Picture
Holly Prentice, PhD
Cell Line Development

Picture
Gene Burton, PhD
Protein Purification

Picture
Divya Goel, MBS
VP of Business Development
Picture
Carlos Garcia, PhD
CMC and Manufacturing

Picture
Parviz Shamlou, PhD
Process Development

Picture
Ian Larson, MBA
Large Scale Manufacturing
Picture
Vinit Saxena, MBA
Chromatography

Picture
Stuart Gallant, MD-PhD
Analytics, QA/QC and Purification
Picture
Picture

​32980 Alvardo Niles Rd.
Union City, CA 94587